JPRN-UMIN000006919
Completed
未知
ong-term Insulin vs Liraglutide Effect on Beta-cell Function in Type 1 Diabetes with Residual Insulin Secretion - SAVE-ISLET
Kitano Hospital, The Tazuke Kofukai Medical Research Institute0 sites40 target enrollmentDecember 25, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 1 diabetes with residual insulin secretion (Slowly Progressive Insulin-Dependent Diabetes millitus, Latent Autoimmune Diabetes in Adults)
- Sponsor
- Kitano Hospital, The Tazuke Kofukai Medical Research Institute
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. The patients who did not agree with this study 2\. The patients with serious complications 3\. The patients with chronic kidney disease higher than stage 4 4\. Those who are not approved to be eligible to this study by corresponding researcher or co\-researchers
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ong-term Insulin vs Liraglutide Effect on Beta-cell Function in Type 1 Diabetes with Residual Insulin Secretion-Extension StudyJPRN-UMIN000006990Kitano Hospital, The Tazuke Kofukai Medical Research Institute20
Active, not recruiting
Not Applicable
The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY) 3. A 2 year, single-centre, open-label, randomised, parallel-group trial comparing insulin therapy to conventional oral sulphonyurea on beta-cell survival.The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY ) 3.MedDRA version: 9.1Level: PTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentEUCTR2008-005263-34-IEThe Mater Foundation/HRB Grant
Recruiting
Not Applicable
Study to determine the relative level of insulin resistance and defect in insulin secretion in diabetic patients of different body habitus.CTRI/2022/02/040316Dr Sarin S M
Active, not recruiting
Phase 1
The effect of a new anti-diabetic drug (Liraglutide) on body weight in patients with type 2 diabetes mellituspatients with type 2 diabetes mellitusMedDRA version: 14.0Level: PTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2011-000411-12-NLMC St Radboud80
Completed
Phase 4
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 DiabetesType 2 Diabetes MellitusNCT03194945Sun Yat-sen University412